Erratum Why Inclusion Matters for Alzheimer's Disease Biomarker Discovery in Plasma
- PMID: 33843689
- DOI: 10.3233/JAD-219318
Erratum Why Inclusion Matters for Alzheimer's Disease Biomarker Discovery in Plasma
Erratum for
-
Why Inclusion Matters for Alzheimer's Disease Biomarker Discovery in Plasma.J Alzheimers Dis. 2021;79(3):1327-1344. doi: 10.3233/JAD-201318. J Alzheimers Dis. 2021. PMID: 33427747 Free PMC article.
Similar articles
-
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.Lancet Neurol. 2020 May;19(5):422-433. doi: 10.1016/S1474-4422(20)30071-5. Lancet Neurol. 2020. PMID: 32333900
-
Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.Brain. 2021 Feb 12;144(1):325-339. doi: 10.1093/brain/awaa399. Brain. 2021. PMID: 33257949 Free PMC article.
-
Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.Lancet Neurol. 2018 Oct;17(10):860-869. doi: 10.1016/S1474-4422(18)30285-0. Epub 2018 Aug 29. Lancet Neurol. 2018. PMID: 30172624
-
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.Lancet Neurol. 2016 Jun;15(7):673-684. doi: 10.1016/S1474-4422(16)00070-3. Epub 2016 Apr 8. Lancet Neurol. 2016. PMID: 27068280 Review.
-
Amyloid-β as a biomarker for Alzheimer's disease: quantification methods in body fluids.Expert Rev Proteomics. 2015 Aug;12(4):343-54. doi: 10.1586/14789450.2015.1065183. Epub 2015 Jul 8. Expert Rev Proteomics. 2015. PMID: 26153725 Review.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources